The life-and-death question is whether these efforts and the largesse of Eli Broad and other patrons of science will be enough to let the U.S. lead the stem-cell revolution.
In recent months, the U.S. Patent Office has put into motion proceedings that could lead key patents on embryonic stem cells to be struck down, meaning that companies that do research on the cells would not give up a share of future profits on their inventions.